secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERACYTE, INC. (VCYT)
CIK:        0001384101
Form:       8-K
Filed at:   2025-05-07T23:59:59+00:00
Accession:  0001384101-25-000058
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Veracyte Q1 2025 revenue $114.5M (+18% YoY); net income $7.0M, Decipher revenue up 33%
--------------------------------------------------------------------------------

- Total revenue $114.5M (+18% YoY); testing revenue $107.3M (+19%); total test volume 40,655 (+22%).
- Decipher revenue $66.6M (+33%); Afirma revenue $38.3M (+6%); Decipher volume ~22,600 (+37%).
- Net income $7.0M (6.2% of revenue); adjusted EBITDA $24.7M (21.6% of revenue).
- Launched limited access to Decipher for metastatic prostate cancer, expanding addressable population.
- Cash and short-term investments $287.4M; generated $5.4M cash from ops.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1384101/000138410125000058/0001384101-25-000058-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1384101/000138410125000058/vcyt-20250507.htm
  HTML page:      https://secwatch.observer/filing/0001384101-25-000058

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer